GenMark Diagnostic

What GenMark Diagnostic does

GenMark Diagnostics is a publicly traded molecular diagnostics company (NASDAQ: GNMK), founded in 2010 and headquartered in Carlsbad, California. The company focuses on developing and commercializing multiplex molecular diagnostic tests built around its proprietary electrochemical sensor detection technology, addressing clinical customers such as hospital laboratories and reference labs that require rapid, sample-to-answer molecular results for infectious disease and other indications.

The company operates at commercial scale, with a workforce in the 501–1,000 employee range and a public-market capital structure. Its disclosed funding history — a $40M growth round led by GE Capital in January 2015, a non-dilutive BARDA award in March 2020, and a $70M financing in May 2020 — indicates active platform commercialization alongside federal-pandemic engagement in 2020. Product, pricing, channel, and detailed portfolio information was not available at the time of analysis because the company's primary website (genmarkdx.com) was inaccessible (Cloudflare 522 connection-timeout error), preventing direct documentation of the assay menu, instrument footprint, and go-to-market mechanics.

GenMark's revenue model in the clinical molecular diagnostics sector is anchored on instrument placements in hospital and reference-lab settings plus recurring consumable (assay cartridge) revenue per test. Public-company scale, the BARDA relationship, and the size of the recent equity raise suggest a franchise with meaningful installed-base economics, though precise revenue figures, customer logos, and segment mix were not contained in the source material. Leadership comprises a Chief Executive Officer (Tanya Monga), a CFO (Paul Ross), and a Founder/President (Scott Mendel), reflecting a founder-influenced management structure typical of venture-backed diagnostics companies that transitioned to public-market status.

Name

GenMark Diagnostic

Website

https://genmarkdx.com

Company type

Private

Founded year

2010

Headcount range

501–1,000 employees

Short description

GenMark Diagnostics is a publicly traded molecular diagnostics company (NASDAQ: GNMK) that develops and commercializes multiplex clinical tests based on its proprietary electrochemical sensor detection technology, serving hospital and reference laboratory customers.

Ownership category

akta.pro rank

Product category

Molecular Diagnostics

NAICS

Medical Laboratories (621511), Medical and Diagnostic Laboratories (62151)

SIC

In Vitro & In Vivo Diagnostic Substances (2835)

akta.pro industry

PRIMARYHLAHAAAD

Molecular Diagnostics (PCR/NAAT/NGS-based IVD)

Healthcare & Life Sciences/Medical Devices & Diagnostics/In Vitro Diagnostics (IVD) & Laboratory Diagnostics

Keywords

• Molecular diagnostics
• Multiplex pathogen testing
• Clinical diagnostic systems
• Infectious disease detection
• Sensor detection technology

Headquarters

HQ city

Carlsbad

HQ country

United States

HQ region

North America

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Supply Chain, Operations, Marketing or Sales, Infrastructure

Core offering

GenMark Diagnostic is a molecular diagnostics company focused on developing and commercializing its proprietary sensor detection technology for clinical diagnostic applications. The company builds multiplex molecular diagnostic testing systems and consumables used by hospital and reference laboratories for the detection of pathogens and genetic targets from patient samples.

Product overview

GenMark Diagnostic is a molecular diagnostics company. Based on the available source data, the company's website (genmarkdx.com) was inaccessible at the time of data collection (Connection timed out - Error 522). No product, service, or portfolio information was available from the aggregated sources to populate product details.

Differentiator

Problem solved

Functional benefit

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Recent moves5 records

Expansion highlights4 records

Broad incumbents

• Cepheid: Cepheid (a Danaher subsidiary) markets the GeneXpert molecular diagnostic system for syndromic infectious disease testing, directly competing with GenMark's ePlex in hospital labs. Comparable on platform breadth, target customer (clinical/hospital labs), and assay menu.
• Hologic: Hologic operates the Panther / Panther Fusion molecular diagnostics platforms and diagnostics business. Same broad diagnostic customer base (clinical labs, hospitals) and molecular diagnostics category as GenMark, though Hologic is a much larger diversified medtech.
• Becton Dickinson (BD): BD's Diagnostic Systems business includes the BD MAX and BD COR molecular platforms as well as the BD Veritor rapid diagnostics. Direct overlap with GenMark in hospital molecular testing menus and customer segments.
• DiaSorin: DiaSorin (through its Luminex acquisition) offers multiplex molecular diagnostic platforms (NxTAG, xMAP, ARIES), overlapping with GenMark's syndromic testing focus. Comparable as a broader IVD platform business with molecular diagnostics exposure.
• Roche Diagnostics: Roche operates cobas Liat, cobas 6800/8800, and MagNA Pure molecular systems, dominating core lab molecular diagnostics. Same end customers (hospital/clinical labs) and assay menus as GenMark, though at much larger scale and broader menu coverage.

Direct peers

• BioFire Diagnostics: BioFire (owned by bioMérieux) is the maker of the FilmArray multiplex PCR system, the dominant syndromic molecular diagnostic platform used in hospitals. Direct competitor to GenMark's ePlex across respiratory, bloodstream, GI, and meningitis/encephalitis panels.
• QuidelOrtho: QuidelOrtho develops and commercializes molecular diagnostics (Savanna, Solana, Lyra product lines) and rapid immunoassay tests. Competes with GenMark for clinical lab customers and offers partially overlapping respiratory infectious disease assays.

Emerging players

• Accelerate Diagnostics: Accelerate Diagnostics develops rapid molecular and phenotypic diagnostics for bloodstream infections, an area where GenMark's bloodstream infection ePlex panel competes. Both target infectious disease diagnostics through novel non-traditional molecular chemistries.
• T2 Biosystems: T2 Biosystems develops molecular diagnostic tests for sepsis and other bloodstream infections using T2MR technology. Targeted overlap with GenMark on bloodstream infection diagnostics and similar small-cap public molecular diagnostics profile.
• Mesa Labs: Mesa Labs, through its BioDot and other acquisitions, plays in adjacent rapid diagnostics and life science measurement, offering a comparable small- to mid-cap IVD profile and order-of-magnitude scale similar to GenMark.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key highlights7 records

Customer concentration

• Xx.com/GenMarkDX
• Facebookfacebook.com/GenMarkDiagnostics
• LinkedInlinkedin.com/company/genmark-diagnostics

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Funding overview

Funding rounds4 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about GenMark Diagnostic